Earnings Call Summary | ISpecimen(ISPC.US) Q4 2023 Earnings Conference
Earnings Call Summary | ISpecimen(ISPC.US) Q4 2023 Earnings Conference
The following is a summary of the ISpecimen Inc. (ISPC) Q4 2023 Earnings Call Transcript:
以下是iSpecimen Inc.（ISPC）2023年第四季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
ISpecimen reported an annual revenue of $9.93 million for the fiscal year 2023, a decrease from $10.4 million in 2022 due to an 11% decrease in the specimen count.
The average selling price per specimen increased from $378 to $404 due to a change in the specimen mix.
The cost of revenue rose slightly by 1% from $4.76M in 2022 to $4.82M in 2023.
They have increased annual expenditure on technology from $4.45 million in 2022 to $5.39 million in 2023, significantly investing in the development of their online marketplace.
Sales and marketing expenses increased by 15% in 2023 due to higher payroll, marketing expenses, and operating costs.
General and administrative expenses witnessed a decrease of 14% for the year ended.
iSpecimen報告稱，由於樣本數量減少了11％，2023財年的年收入爲993萬美元，低於2022年的1,040萬美元。
由於樣本組合的變化，每個樣本的平均銷售價格從378美元上漲到404美元。
收入成本從2022年的476萬美元小幅增長了1％，至2023年的482萬美元。
他們已將每年的技術支出從2022年的445萬美元增加到2023年的539萬美元，大量投資於在線市場的發展。
由於工資、營銷費用和運營成本的增加，2023年的銷售和營銷費用增長了15％。
截至年底，一般和管理費用下降了14％。
Business Progress:
業務進展：
iSpecimen focused on technology advancements, including improved search functionality, increased automation, and matchmaking.
The company has improved its sales funnel speed and won rates with its matchmaking module and Next-Day Quote initiative.
They have progressed its cancer sequencing program, which aims to provide on-demand access to sequence biospecimens.
A new sales strategy has been launched focusing on team and line of business-oriented structures with a focus on key account management.
The company launched a partnership with TriMetis Life Sciences to standardize and enhance tissue sample evaluation.
Several marketing initiatives and realigned sales efforts resulted in considerable sales in December 2023, the highest in the company's history.
They have commenced a supplier contract refresh program to improve supplier engagement.
Plans to streamline operations, reduce costs and focus on key market opportunities in 2024 are in place.
ISpecimen entered an aftermarket offering agreement to sell shares of common stock up to $1.5 million for additional funding.
iSpecimen專注於技術進步，包括改進搜索功能、提高自動化程度和配對。
該公司通過其配對模塊和次日報價計劃提高了銷售渠道速度和中標率。
他們已經推進了癌症測序計劃，該計劃旨在按需提供序列生物標本的訪問權限。
已經啓動了一項新的銷售戰略，該戰略側重於以團隊和業務爲導向的結構，重點是關鍵客戶管理。
該公司與TrimeTis生命科學建立了合作伙伴關係，以標準化和加強組織樣本評估。
多項營銷舉措和調整後的銷售工作使2023年12月的銷售額可觀，創下公司歷史最高水平。
他們已經啓動了供應商合同更新計劃，以提高供應商參與度。
2024年精簡運營、降低成本和關注關鍵市場機會的計劃已經制定。
iSpecimen簽訂了售後發行協議，出售不超過150萬美元的普通股以獲得額外資金。
More details: iSpecimen IR
更多詳情： iSpecimen IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。